114 results on '"Riis, B.J."'
Search Results
2. OA phenotypes, rather than disease stage, drive structural progression – identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA
3. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials
4. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis
5. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study
6. Calcitonin is involved in cartilage homeostasis: Is calcitonin a treatment for OA?
7. The Effect of Fluvastatin on Parameters of Bone Remodeling
8. Biomarkers of bone and cartilage turnover CTX-I and CTX-II predict total joint replacements in osteoarthritis
9. FRI0530 Total joint replacement (TJR) as clinical endpoint in oa; prevalence and incidence rates of tjrs from the prospective epidemiologic risk factor (PERF I) study
10. Total joint replacement (TJR) as clinical endpoint in OA; prevalence and incidence rates of TJRS from the Prospective Epidemiologic Risk Factor (PERF I) study
11. Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study
12. Pain sub-types and clinical characteristics associated with placebo response in OA: Data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis
13. Investigating clinical differences of three different osteoarthritis phenotypes identified by two clinically tested biomarkers
14. OP0248 Responder Analysis of the Effects of Abaloparatide (Parathyroid Hormone Related Peptide) and Teriparatide on Bone Mineral Density in Postmenopausal Women with Osteoporosis: Results of the Active Trial
15. THU0454 OA Pain Phenotypes Associated with Structural Progression and Change in Pain Over Time in Two Phase III Clinical Studies with Symptomatic Knee OA
16. AB0839 Identification of a Inflammatory Phenotype with Higher Likelihood of Progression in OA: Analysis of Womac Pain Sub-Questions, C3M and U-CTX-II from Two Phase 3 Randomized Clinical Trials with Treatment of Symptomatic Knee Osteoarthritis
17. THU0453 Biomarkers of Bone and Cartilage Remodeling in OA is Strongly Associated with Pain and Obesity: Data from Two Phase 3 Randomized Clinical Trials in Symptomatic Knee OA
18. Segregating OA patients with and without joint inflammation using two biomarkers of connective tissue inflammation
19. Identification of an inflammatory phenotype with higher likelihood of progression in OA: Analysis of womac pain sub-questions, C3M and U-CTX-II from two phase 3 randomized clinical trials with treatment of symptomatic knee osteoarthritis
20. Identification of OA pain phenotypes associated with structural progression
21. MRI analysis from two phase 3 randomized clinical trials; treatment of symptomatic knee osteoarthritis with oral salmon calcitonin
22. Association between joint space width, Kellgren-Lawrence score, pain and progression in osteoarthritis subjects from two phase III studies – a clinical study reference database
23. 64 ORAL CALCITONIN DEMONSTRATED SYMPTOM-MODIFYING EFFICACY AND INCREASED CARTILAGE VOLUME: RESULTS FROM A 2-YEAR PHASE 3 TRIAL IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
24. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP) — Assessment of corresponding epitopes
25. 564 EFFICACY AND SAFETY OF ORAL SALMON CALCITONIN IN PATIENTS WITH KNEE OSTEOARTHRITIS: RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
26. 247 BONE AND CARTILAGE DEGRADATION ARE COUPLED UNDER SOME PATHOLOGICAL AND PHYSIOLOGICAL PROCESSES
27. 338 INVESTIGATIONS OF INTER- AND INTRA-INDIVIDUAL RELATIONSHIPS BETWEEN ABSORPTION OF ORAL SALMON CALCITONIN AND A SURROGATE MARKER OF PHARMACODYNAMIC EFFICACY
28. 284 AN ORAL RECOMBINANT FORM OF SALMON CALCITONIN SUPPRESSES BOTH BONE RESORPTION AND CARTILAGE DEGRADATION
29. Design for an ipriflavone multicenter European fracture study
30. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture. A 15-year follow-up study
31. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study
32. Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up Study
33. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use
34. 92164556 Sequential estrogen and progesteron therapy: Assessment of progestational effects on the postmenopausal endometrium
35. Serum placental protein 14 (PP14) reflects endometrial status during hormone replacement therapy
36. 92010558 Desogestrel in hormone replacement therapy: Long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding
37. Secretory endometrial protein PP14 in serum from post-menopausal women receiving continuous combined oestradiol-cyproterone acetate: Correlation with serum hormone concentrations and bleeding patterns
38. 91313094 Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study
39. Review: Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials.
40. 91167155 Bleeding patterns during continuous combined estrogen-progestogen therapy
41. 91205749 Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives
42. 90382258 Collagen synthesis in postmenopausal women during therapy with anabolic steroid or female sex hormones
43. 91046490 Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern
44. 91024665 Comparison of vitamin D metabolism in early healthy and late osteoporotic postmenopausal women
45. 90318000 17β-Estradiol and continuous norethisterone: A unique treatment for established osteoporosis in elderly women
46. Changes in vitamin D metabolism during natural and medical menopause
47. Vitamin D metabolism in osteoporotic women during treatment with estrogen, an anabolic steroid, or calcitonin
48. The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: The effect of nandrolone decanoate and female sex hormones
49. Hormonal replacement therapy and the skeletal system
50. Serum placental protein 14 in pre-menopausal and post-menopausal women — dependency on oestrogen/progestogen status
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.